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The sirtuins are NAD+-dependent protein deacetylases and/or ADP-ribosyltransferases
that play roles in metabolic homeostasis, stress response and potentially aging. This
enzyme family resides in different subcellular compartments, and acts on a number
of different targets in the nucleus, cytoplasm and in the mitochondria. Despite their
recognized ability to regulate metabolic processes, the roles played by specific sirtuins in
the brain—the most energy demanding tissue in the body—remains less well investigated
and understood. In the present study, we examined the regional mRNA and protein
expression patterns of individual sirtuin family members in the developing, adult, and aged
rat brain. Our results show that while each sirtuin is expressed in the brain at each of these
different stages, they display unique spatial and temporal expression patterns within the
brain. Further, for specific members of the family, the protein expression profile did not
coincide with their respective mRNA expression profile. Moreover, using primary cultures
enriched for neurons and astrocytes respectively, we found that specific sirtuin members
display preferential neural lineage expression. Collectively, these results provide the first
composite illustration that sirtuin family members display differential expression patterns
in the brain, and provide evidence that specific sirtuins could potentially be targeted to
achieve cell-type selective effects within the brain.
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INTRODUCTION
The family of mammalian sirtuins consists of seven members
(SIRTs 1-7), which collectively comprise the class III protein
deacetylases (reviewed in Michan and Sinclair, 2007). These
sirtuins are descendants from the ancestral yeast gene Sir2,
which was originally identified as a silent mating factor (Frye,
2000; Greiss and Gartner, 2009). These mammalian sirtuins
function as NAD+-dependent protein deacetylases and/or ADP-
ribosylases that exert their actions largely in distinct subcellular
compartments. SIRT1, SIRT6, and SIRT7 are found primarily
within the nucleus, where they target proteins in nucleoplasm,
along heterochromatin and associated with nucleoli, respectively
(Michishita et al., 2005). Although predominantly nuclear, there
is also evidence that at least SIRT1 can shuttle to the cytosol under
certain conditions (Michishita et al., 2005; Jin et al., 2007). In
contrast, SIRT3, SIRT4, and SIRT5 localize primarily withinmito-
chondria (Onyango et al., 2002; Ahuja et al., 2007; Nakagawa
et al., 2009), while SIRT2 is predominately found in the cyto-
plasmic compartment of cells (North et al., 2003). Converging
evidence has implicated the function of specific sirtuin family
members in different aspects of cellular regulation, including lipid
homeostasis and metabolism (reviewed in Houtkooper et al.,
2012), oxidative stress management (reviewed in Rajendran et al.,
2011), and apoptosis resistance (reviewed in Pantazi et al., 2013).
As these sirtuin targets are believed to contribute to aging pro-
cesses, there is speculation that sirtuin family members may play
direct roles in longevity regulation (Guarente, 2013). The catalytic
activity of the different sirtuins increases or decreases depend-
ing on factors such as the availability of NAD+, levels of cellular
stress, glucose availability, oxidative load, and/or the energy pro-
duction demands within the individual cell (Pillai et al., 2005;
Yang et al., 2007; Ying and Xiong, 2010; Braidy et al., 2011; Zerp
et al., 2014). Thus, sirtuins appear to serve as metabolic and stress
sensors whose activity can regulate the homeostatic balance of
cells in response to changing environmental conditions.
Despite these data illustrating the prominent role of sirtuins in
cellular homeostasis, relatively little information currently exists
regarding their expression magnitude and spatial distribution
within the central nervous system. Given that the brain utilizes
approximately 20% of total body energy expenditure (reviewed in
Herculano-Houzel, 2011), an understanding of sirtuin expression
in this metabolically active tissue could aid in delineating their
role in both normal physiological processes and also potentially
in pathophysiological conditions. To begin addressing this issue,
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we examined the endogenous mRNA and protein expression pat-
terns of the seven sirtuin family members in the adult, developing
and aged rat brain, and compared their relative expression within
the two predominant cell types of the brain, specifically neurons
and astrocytes. Our results indicated that while each sirtuin is
expressed within the brain, there are dramatic differences between
their expression patterns at the spatial and ontogenetic levels.
MATERIALS AND METHODS
ANIMAL USE AND TISSUE COLLECTION
Animal experimentation was conducted in accordance with the
guidelines of the Canadian Council of Animal Care, and protocols
for animal use were reviewed and approved by the local University
Health Network animal care committee before initiation of the
study. Male Wistar rats and timed pregnant female Wistar rats
were purchased from Charles River Laboratories (Sherbrooke,
Quebec). SIRT3-null mice and wild-type mice were obtained
from Jackson Laboratories (SIRT3-KO mice, cat # 012755, wild-
type mice, cat #000664; Bar Harbor, ME). Cortical tissue was
harvested from these mice for SIRT3 antibody validation. For
expression analysis Wistar rats were used as subjects. These sub-
jects were euthanized by decapitation while under isoflurane
anesthesia, and specific brain and peripheral tissues were collected
by dissection (whole brain, cortex, hippocampus, cerebellum,
brain stem, spinal cord, striatum, olfactory bulb, heart, liver,
spleen, kidney, small intestine) at different ages (embryonic day
18 (E18), postnatal day (PN) 2, 7, 21 and 3, and 24 months). The
gender of the subjects used for tissue collection was not specifi-
cally determined for E18, PN2, PN7 or PN21 stages, while female
rats were used for the 3 and 24 month tissue samples. These
dissections were conducted on an ice-cold glass plate, and the iso-
lated tissues snap frozen by submersion in liquid nitrogen. Frozen
tissues were stored at −80◦C until homogenization for RNA or
protein examinations.
ESTABLISHMENT OF NEURON-ENRICHED PRIMARY CORTICAL
CULTURES
Cortical tissue was isolated from fetuses obtained at embryonic
day 18 (E18) from timed-pregnant Wistar rats (Charles River
Laboratories). The head of each embryo was dissected away from
the body, and placed in 20ml 1× Hank’s Balanced Salt Solution
(HBSS) (Invitrogen-Life Technologies, Burlington, Ontario, cat
# 14175103). Brains were removed and placed in a separate
dish containing 20ml supplemented HBSS. Cortices were dis-
sected from whole brains using micro dissection forceps, and the
collected tissue was incubated in 2ml of 0.05% trypsin (Sigma–
Aldrich, St. Louis, MO, cat # 59417C) at 37◦C for 15min. The
tissue was then triturated by glass pipette 10–15 times to disperse
the cells in seeding medium (Dulbecco’s Modified Eagle Medium
(DMEM) /F-12) (Invitrogen, cat # 21041025) containing 10%HS
and then centrifuged for 5 min at 21,000 × g to pellet the cells.
The cells were re-suspended in Neurobasal medium (Invitrogen,
cat # 21103049) containing 2% B-27 supplement (Invitrogen,
cat # 17504-044), 1% FBS, 0.5mM L-glutamine (Invitrogen, cat
# 25030-149) and cell counts done using Trypan Blue (Sigma–
Aldrich, cat # T8154) as a viability indicator. The cells were
then seeded in plating medium at a density of 30,000 cells/well
in 96-well plates. After 96 h of isolation, the plating media was
exchanged with maintenance medium (Neurobasal medium con-
taining 2% B-27 supplement, 0.5mM L-Glutamine) contain-
ing 4μM cytosine arabinoside (Sigma-Aldrich, cat # C6645) to
inhibit proliferation of any residual non-neuronal cells. The pri-
mary cultures were fed withmaintenancemedium every 3–4 days,
and the neurons were harvested for assay at 12–14 days after
plating.
PREPARATION OF ASTROCYTE-ENRICHED CULTURES
Astrocyte enriched cultures were generated from cortical tissue
isolated from post-natal day 1-2 rat pups. In short, following
decapitation, cortical tissue was isolated by dissection, placed in
ice-cold HBSS, and the meninges removed by dissection. The tis-
sue was then rinsed in HBSS, placed in a minimal amount of
media, and chopped into 1mm3 cubes by manual dissection. The
brain cubes were then incubated with 0.05% Trypsin for 30min
at 37◦C, and dissociated by triturating 12–15 times with polished
Pasteur pipette. The cells were then collected by centrifugation at
21,000 × g for 5min, re-suspended in Astrocyte Medium con-
taining 1× N2 Supplement (Invitrogen, cat # 17502048), 2mM
Glutamax, Penicillin/Streptomycin, supplemented with 5 ng/ml
EGF (Sigma-Aldrich, cat # SRP3052) as per manufacturer’s
instruction. Trypan Blue was used to count viable cells and the cell
suspension was then plated in at a density of 1,000,000 cells/well
in 6-well plates.
QUANTITATIVE REAL TIME PCR
To quantify sirtuin mRNA expression levels, rats were sacrificed
by decapitation, and specific brain regions isolated by dissection
on an ice-cold glass plate. RNeasy Mini Kit (Qiagen, Valencia,
CA, cat # 74104) was used to extract total RNA from the tis-
sue as per manufacturer’s guidelines. Purified total RNA (1μg)
was then reverse transcribed into cDNA using the Superscript
II First Strand Synthesis System (cat # 18064-014, Invitrogen).
Pre-designed Taqman probe and primer mixtures (Applied
Biosystems-Life Technologies, Burlington, Ontario) were used to
assess mRNA expression: Sirt2 (cat # Rn01457502_m1), Sirt3 (cat
# Rn01501412_m1), Sirt4 (cat # Rn01481485_m1), Sirt5 (cat #
Rn01450559_m1), Sirt6 (cat # Rn01408249_m1), and Sirt7 (cat
# Rn01471420_m1), using hypoxanthine-guanine phosphoribo-
syltransferase (Hprt1) (cat # Rn_01527831_g1) as a reference
control. Because Taqman primers were not available for rat
Sirt1, SYBR Green forward and reverse primers were designed
that spanned an intron of the rat Sirt1 sequence (forward: 5′-
cagcaacacctcatgattgg-3′, reverse: 5′-tcccacaggaaacagaaacc-3′) and
also for the reference Hprt1 (forward: 5′-gcagactttgctttccttgg-
3′, reverse: 5′-cgagaggtccttttcaccag-3′). We selected Hprt1 as the
housekeeping gene for our mRNA quantification studies as it
is expressed ubiquitously and stably in various tissues (Fischer
et al., 2005; Wei et al., 2013), and it has been used as an inter-
nal control for mRNA normalization in previous developmental
studies (Franco-Montoya et al., 2011; Murta et al., 2013). All
PCR samples were assayed in quadruplicate on a 384-well plate
using Taqman master mix reagent kit (Applied Biosystems, cat
# 4304437) or SYBR Green (Applied Biosystems, cat # 4368577)
using 20 ng of cDNA generated from total isolated RNA as
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template in 10μl reactions on a 7900HT Fast Real-Time PCR
System (Applied Biosystems). The thermal profile for the Taqman
assays was as follows: one cycle of enzyme activation at 50◦C
for 2min and template denaturation at 95◦C for 10min, fol-
lowed by 40 cycles of 95◦C for 15 s, primer annealing at 60◦C
for 1min, and template extension at 72◦C for 30 s. For SYBR
Green assays, the thermal profile was: one cycle of enzyme acti-
vation at 50◦C for 2min followed by denaturation at 95◦C for
10min, followed by 40 cycles of 95◦C for 15 s, primer annealing
at 56 or 60◦C for 1min, and template extension at 72◦C for 30 s.
The amplification of all the primers was analyzed with using the
Applied Biosystems Sequence Detection System software (SDS v.
2.2). For mRNA expression, critical threshold (Ct) cycle values
were identified for each sirtuin being assayed relative the expres-
sion of the Hprt1 reference gene, and the results expressed as fold
differences from Hprt1 using the 2−Ct formula, where Ct =
Ct(Sirt) − Ct (Control). For mRNA expression comparisons
between the astrocyte and neuronal enriched cultures, the expres-
sion of Hprt1 was used as a common reference. The Ct values for
Hprt1 expression were equivalent between the two cultures (not
shown).
ANTIBODIES ANDWESTERN BLOTTING
Following harvest, cultured cells were homogenized in tissue lysis
buffer consisting of 50mM Tris—pH 8.0, 1% NP40, 150mM
NaCl, 1mM EDTA, 1mM PMSF, 1μg/ml Aprotinin, 1μg/ml
Leupeptin, 2mM Na3VO4 and supplemented with 1 tablet of
protease inhibitor cocktail (Roche, cat # Mississauga, Ontario,
cat # 11836153001). Frozen tissue was minced while still lightly
frozen and homogenized as above in lysis buffer. Following
homogenization through a 21 gauge needle, the samples were
centrifuged at 21,000 × g for 10min at 4◦C. The supernatant
was then collected, and total protein concentration determined
using the Bio-Rad protein assay (Biorad, Mississauga, Ontario,
cat # 162-0115). For immunoblots, 20μg of total protein sam-
ples were resolved on 12% SDS-PAGE, at a constant voltage
of 100V for 2 h. The proteins resolved in the gel were then
transferred to PVDF membranes (PALL, Mississauga, Ontario,
cat # 66543) overnight in transfer buffer (25mM Tris, 192mM
glycine, and 0.1% SDS) at 4◦C at a constant voltage of 25V.
The membranes were then blocked for 2 h in non-fat powdered
milk (5%) in TBST washing buffer (10mM Tris, 150mM NaCl,
0.05% Tween 20), and probed overnight at 4◦C with a the pri-
mary antibody of interest. The antibodies and dilutions used
are: rabbit polyclonal anti-SIRT1 (1:10,000; Millipore, Billerica,
MA, cat # 07-131); rabbit polyclonal anti-SIRT2 (1:2000; Sigma-
Aldrich, cat # S8447); rabbit monoclonal anti-SIRT3 (1:500;
Cell Signaling, Beverly, MA, cat # 2627); rabbit monoclonal
anti-SIRT3 (1:500; Cell Signaling, cat # 5490), rabbit polyclonal
anti-SIRT4 (1:1000; Sigma–Aldrich, cat # S0948); rabbit poly-
clonal anti-SIRT5 (1:500; Millipore, cat # ABE198); rabbit poly-
clonal anti-SIRT6 (1:1000; Sigma-Aldrich, cat # S4322); rabbit
polyclonal anti-SIRT7 (1:250 to 1:3000; Sigma-Aldrich, cat #
AV32406); mouse monoclonal anti-glial fibrillary acidic protein
(GFAP) (1:15,000; Cell Signaling, cat # 3670); mouse monoclonal
anti-microtubule associated protein 2 (MAP2) (1:500; Sigma–
Aldrich, cat # M1406); mouse monoclonal anti-NG2 (1:500;
Chemicon-Millipore, cat # MAB5384). After washing in TBST 3
times for 15min each, the blots were incubated with the appropri-
ate horseradish peroxidase (HRP)-linked secondary anti-rabbit
raised in sheep (1:5000; GE Healthcare, cat # NA934V) or anti-
mouse raised in donkey (1:5000; GE Healthcare, cat # NA931V)
antibodies at room temperature for 2 h, and washed in TBST as
above. Immunoreactivity was visualized usingWestern-Lightning
Chemiluminescence Reagent Plus (PerkinElmer, Waltham, MA,
cat # NEL-105) on X-Ray film (Denville Scientific, Metuchin,
NJ, cat # E-3018). To allow normalization for minor variances in
protein loading between sample lanes, the blots were re-probed
for anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
(1:5000; Chemicon-Millipore cat # MAB374), Beta-actin (1:1000;
Cell Signaling, cat # 51525) or stained with Coomasie blue (0.1%
Coomassie Brilliant Blue R250, 10% acetic acid, Sigma-Aldrich).
Coomasie staining was used as the normalization control for
examination of peripheral tissue expression levels. This latter
means of normalization was required, as classic loading controls
such as GAPDH have not proven reliable when comparing across
different tissues and/or specific cell types from the same animal
(Eaton et al., 2013). Quantity One software (BioRad) was used to
analyze scanned Autoradiography films (Denville Scientific, cat #
E3018). Optical densities of all bands weremeasured in OD/mm2,
with film background subtracted to give the final densitometric
values.
VALIDATION OF ANTIBODY SPECIFICITY
PC12 cells were grown in at 37◦C in a humidified incubator
under 5% CO2 conditions. The culture medium was RPMI 1640
(Gibco-Life Technologies, Burlington, ON, cat # 11875-093), sup-
plemented with 10% horse serum (HS) (Gibco, cat # 16050-122),
5% fetal bovine serum (FBS) (Gibco, cat # 16000-044), and
50 U/ml penicillin-streptomycin (Gibco, cat # 15240-062). The
specificity of each individual sirtuin antibody was determined
by assessing non-treated and siRNA-treated PC12 cells for the
appropriate sirtuin. The specific siRNAs and concentrations used
were: Sirt1 (50 nM, Sigma-Aldrich, cat # SASI_Rn0200230695),
Sirt2 (13 nM, Ambion-Life Technologies, Burlington, Ontario,
cat # S16750), Sirt4 (13 nM, Ambion, cat # S156091), Sirt5
(50 nM, Ambion, cat # S157785), Sirt6 (50 nM, Ambion, cat
# S152314), Sirt7 (50–200 nM, Ambion, cat # S155507), and a
scrambled siRNA control at matching concentrations (Ambion,
cat # AM4611) was used as a negative control for each respective
comparison. After 24 h of transfection, whole cell lysates were col-
lected and analyzed by western blotting. For SIRT3, cortical tissue
from SIRT3-KO mice was used to confirm antibody specificity, as
PC12 cells did not display readily discernible endogenous SIRT3
immunoreactivity under basal conditions (not shown). Cortical
tissue was isolated and processed as described above.
STATISTICAL ANALYSIS
Statistical analysis was performed using either student’s t-test or
One-Way ANOVA in GraphPad Prism version 5.00 (GraphPad
Software, San Diego CA), with Tukey’s post-hoc test for multi-
ple comparisons where appropriate. All results are expressed as
mean ± standard error of means (SEM) and p < 0.05 was set as
the level of statistical significance.
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FIGURE 1 | Sirtuins are expressed at different levels in the adult rat
brain.Histogram showing Sirt1-7 mRNA expression levels in the whole adult
rat brain as determined by qRT-PCR. The y-axis shows the relative sirtuin
expression levels relative to theHprt1 reference gene. Note the broken y-axis
scale for Sirt2, Sirt3 and Sirt5. Data shown are based on the linear conversion
of delta CT values for each sample (n = 3, error bars denote SEM). Statistical
comparisons between the expression levels of the different sirtuins in the
adult brain are presented in Supplemental Table 1.
RESULTS
Sirt1
Sirt1 mRNA was found by quantitative RT-PCR to be one of
the least expressed sirtuin family members in brain. Sirt1 mRNA
levels were significantly lower than Sirt2, Sirt3, and Sirt5 in the
whole brain, and were present at similar levels to Sirt4, Sirt6,
and Sirt7 (Figure 1). Within different brain regions, Sirt1 mRNA
was found at similarly low levels, with only modest variabil-
ity seen between different adult brain regions. The highest Sirt1
mRNA levels were in cerebellum, while the lowest were in spinal
cord (Figure 2A). At the protein level, siRNA treatment identi-
fied one specific SIRT1 product of 110 kDa (Supplemental Figure
1A). SIRT1 protein prevalence paralleled its mRNA pattern, being
highest in the cerebellum, intermediate in the cortex, hippocam-
pus, striatum and the olfactory bulb, and lowest in the spinal
cord (Figure 3A). Relative to its expression in peripheral tissues,
Sirt1 mRNA levels in liver were similar to whole brain; spleen
and kidney expressed higher levels of Sirt1 mRNA than brain,
while heart and small intestine expressed lower levels of Sirt1
than brain (Table 1; Supplemental Figure 3A). This pattern was
not recapitulated at the protein level, however, as SIRT1 protein
expression was significantly higher in the brain than in any of
these peripheral tissues (Supplemental Figure 4A).
During brain development, Sirt1 mRNA levels decreased pro-
gressively relative to the reference geneHprt1 from the late embry-
onic stage in cortex, hippocampus, and cerebellum (Table 2;
Figures 4A, 6A, 8A). This developmental mRNA expression pat-
tern was not brain-specific, as a similar pattern was also observed
in liver (Supplemental Figure 5A; Supplemental Table 12). At
the protein level, this general pattern was recapitulated, as SIRT1
protein expression was significantly higher in cortex and hip-
pocampus at E18 and early postnatal stages compared to the adult
and 24 month old stages (Table 2; Figures 5A, 7A). A slightly dif-
ferent pattern was observed in cerebellum, as while SIRT1 protein
levels were lower in adult than in perinatal stages, the decrease in
prevalence did not occur until after postnatal day 21 (Figure 9A).
In each brain region, SIRT1 protein prevalence at 3 and 24
months were similar, respectively, indicating the absence of an
aging-associated decrease in SIRT1 protein prevalence. This pro-
gressive decrease in SIRT1 protein during perinatal development
appeared to be brain-selective, as SIRT1 protein levels increased
in the liver during perinatal development, and then remained at
similar levels until the 24 month stage (Supplemental Figure 6A;
Supplemental Table 13).
Analysis of Sirt1 expression between astrocytes and neurons
revealed that while Sirt1 mRNA was detected in extracts from
each of these respective cultures, its mRNA levels were 84.0 ±
0.3% higher in the astrocyte cultures than in the neuronal cultures
(p < 0.05; Figure 10A). Consistent with its low expression in the
adult brain, Sirt1 mRNA was also relatively low compared to the
other sirtuins except Sirt4 in each of these cultured cell types. At
the protein level, though, SIRT1 prevalence differed somewhat
from its mRNA profile in these cultures. Although SIRT1 pro-
tein was also detected in both the neuron and astrocyte-enriched
cultures, its overall prevalence was 68.5 ± 18.4% higher in the
neuronal cultures than in the astrocytes (p < 0.05; Figure 10B).
Sirt2
Quantitative RT-PCR revealed that Sirt2 is the most abundantly
expressed sirtuin in the rat brain at the mRNA level (Figure 1),
where its expression was found to bemore than 3-fold higher than
the reference Hprt1 gene (Supplemental Figure 2B). Within the
different adult brain regions, Sirt2 mRNA was highest in spinal
cord, brain stem, and striatum, and at similar levels in cortex,
hippocampus, cerebellum and olfactory bulb (Figure 2B). At the
protein level, SIRT2 protein expression patterns were similar its
mRNA patterns, being most pronounced in the spinal cord and
brain stem, but still showing strong immunoreactive prevalence
in cortex, hippocampus, striatum and cerebellum (Figure 3B).
Sirt2 mRNA was also present at high levels relative to its fam-
ily members in peripheral tissues, but only the kidney expressed
Sirt2 mRNA at levels equivalent to those in the adult brain
(Table 1; Supplemental Figure 3B). At the protein level, siRNA
treatment identified one specific SIRT2 protein product of 37 kDa
(Supplemental Figure 1B). SIRT2 protein prevalence in heart,
liver, and spleen were similar to its brain levels, while its protein
prevalence in small intestine and kidney were at lower levels than
in the adult brain (Table 1; Supplemental Figure 4B).
The developmental expression pattern of Sirt2 mRNA relative
to the Hprt1 reference gene in the cortex and hippocampus was
highest at E18, and then remained fairly consistent across peri-
natal development and into adulthood (Table 2; Figures 4B, 6B).
A spike of Sirt2 mRNA was observed at PN21, but this increase
was transient and not retained in the 3 month old cortex or hip-
pocampus (Figures 4B, 6B). The expression profile of Sirt2 was
somewhat different in the cerebellum, where Sirt2 mRNA dis-
played a transient increase at PN7 and PN21 compared to E18 and
PN2, and then decreased to consistent levels seen in both the adult
and 24 month old tissues (Figure 8B). Intriguingly, however, this
mRNA profile for Sirt2 was not recapitulated at the protein level,
as SIRT2 immunoreactivity was minimal or at background lev-
els in samples prior to the PN21 stage in cortex, hippocampus,
and cerebellum. SIRT2 protein then rapidly appeared at PN21
in each of these brain regions, and remained at fairly consistent
Frontiers in Aging Neuroscience www.frontiersin.org December 2014 | Volume 6 | Article 333 | 4
Sidorova-Darmos et al. Spatial and temporal expression of sirtuins in brain
FIGURE 2 | Sirtuins display differential gene expression levels within
different regions of the adult rat brain. Histograms showing the mean and
SEM of the mRNA expression levels for each individual sirtuin in the indicated
brain regions as determined by qRT-PCR. The y-axis shows the mRNA
expression levels for (A) Sirt1 (B) Sirt2 (C) Sirt3 (D) Sirt4 (E) Sirt5 (F) Sirt6
(G) Sirt7 relative to the Hprt1 reference gene in each of the denoted brain
regions. Data shown are based on the linear conversion of delta CT values for
each sample (n = 3, error bars denote SEM). Statistical comparisons for the
expression levels of each sirtuin in these adult brain regions are presented in
Supplemental Table 2.
levels until 24 months of age (Table 2; Figures 5B, 7B, 9B). In
adult peripheral tissues, Sirt2 mRNA and protein were expressed
at varying levels relative to brain, with SIRT2 protein in heart,
liver and spleen similar to or slightly above those found in adult
brain (Supplemental Figures 3B, 4B). During liver development,
Sirt2 mRNA was expressed from PN2-24 months at similar lev-
els, but was modestly higher at the E18 stage (Supplemental
Figure 5B; Supplemental Table 12). SIRT2 protein in the devel-
oping liver largely paralleled this pattern, but unlike Sirt2 mRNA,
SIRT2 protein displayed a significant increase in prevalence at
the 3 month stage, before returning to levels similar to perinatal
times at 24months of age (Supplemental Figure 6B; Supplemental
Table 13).
The analysis of Sirt2 expression in the neuron and astro-
cyte cultures also yielded intriguing results. Consistent with its
expression levels in whole brain, Sirt2 mRNA was the most
prominently expressed sirtuin family member in each culture,
although the astrocytes displayed approximately 7-fold higher
Sirt2 mRNA than neurons (Figure 10A). This mRNA pattern
was not recapitulated at the protein level, however. In fact, while
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FIGURE 3 | Sirtuin protein expression patterns are non-redundant in
different regions the adult rat brain. Representative Western blots
showing the immunoreactive protein levels for (A) SIRT1 (B) SIRT2
(C) SIRT3 (D) SIRT4 (E) SIRT5 (F) SIRT6 in the different regions of
the adult rat brain as denoted. The histograms in each panel show
the densitometric mean and SEM for each specific sirtuin normalized
to its corresponding GAPDH loading control (n = 4 independent
subjects). Statistical comparisons between sirtuin protein expression
patterns in these adult brain regions are presented in Supplemental
Table 3.
SIRT2 immunoreactivity was readily detected in extracts from
the astrocyte-enriched cultures, its immunoreactivity in extracts
from the neuronal cultures was at, or only slightly above, back-
ground levels (Figure 10C). Thus, despite having pronounced
mRNA expression in neurons, SIRT2 protein was not readily
detected in the same cultured neurons.
Sirt3
At the mRNA level, Sirt3 was the third most expressed mem-
ber of the sirtuin family in the whole brain (Figure 1), and in
each of the different adult brain regions examined except cere-
bellum, where its expression was modestly lower (Figure 2C). At
the protein level, SIRT3 specific products were identified using
cortical tissue derived from a SIRT3-null mouse (Lombard et al.,
2007), which identified one specific SIRT3 product of 28 kDa
(Supplemental Figure 1C). SIRT3 protein levels largely paralleled
its mRNA expression patterns in the adult brain, being at sim-
ilar levels within cortex, hippocampus, striatum, spinal cord
and brain stem, and at modestly lower levels in the cerebellum
(Figure 3C). With respect to peripheral tissues, the kidney dis-
played Sirt3 mRNA levels similar to those of whole brain, while
each of the other tissues examined showed lower Sirt3 mRNA
levels than brain (Table 1; Supplemental Figure 3C). At the pro-
tein level, though, there was considerable variations in SIRT3
immunoreactivity in these tissues: SIRT3 protein prevalence in
heart was higher than in brain, the spleen and small intestine had
lower SIRT3 expression than brain, and the kidney and liver had
similar SIRT3 levels as brain (Table 1; Supplemental Figure 4C).
The mRNA expression pattern of Sirt3 during development
was relatively similar in cortex, hippocampus, and cerebellum,
with Sirt3 mRNA levels being fairly consistent from E18 until
24 months of age (Table 2; Figures 4C, 6C, 8C). The pattern of
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Table 1 | Relative mRNA and protein expression patterns of specific sirtuin members in brain and peripheral tissues.
mRNA expression Sirt1 Sirt2 Sirt3 Sirt4 Sirt5 Sirt6 Sirt7
Whole brain ++ + + ++ ++ + + + + ++ ++
Heart + + + + ++ + + + + + +
Liver ++ + + + ++ + ++ + ++
Spleen ++ + + + ++ + ++ + ++
Kidney ++ + + ++ ++ ++ + + + ++ ++
Intestine + + + + ++ + + + + ++ + + +
Protein expression SIRT1 SIRT2 SIRT3 SIRT4 SIRT5 SIRT6 (36 KDa) SIRT6 (39 KDa)
Whole brain ++ + + ++ + + + ++ ++ + ++
Heart ++ + + + + + + + ++ ++ ++ + ++
Liver ++ + + + + + + + + ++ + + + + + + 0
Spleen 0 + + + + + 0 + + + + ++ +
Kidney 0 + + + + + + ++ + + + + + + +
Intestine 0 0 0 + 0 0 ++
In the upper mRNA expression panel, “+” are assigned based on the specified range of Ct values for the Sirtuin expression levels relative to the Hprt1 control
gene, such as: + + + + + = >3 Ct; + + ++ = Ct 1.5 – 3; + + + = Ct 0.5 – 1.5; ++ = Ct 0.05 – 0.5; and + = Ct < 0.05. In the lower protein expression
panel, “+” are assigned based on their relative expression values for the sirtuin expression levels when compared to GAPDH control, such as: + + + + +, very
high; + + ++, high; + + +, moderate; ++, low; and +, very low levels of expression. “0” was assigned to areas of no expression.
SIRT3 protein expression was quite different, however, as a robust
increase in SIRT3 protein prevalence was observed in cortex and
hippocampus between PN7 and PN21, and this level was main-
tained in the 3 and 24 month old samples (Table 2; Figures 5C,
7C). In cerebellum, SIRT3 protein prevalence was similar between
E18 to 3 months, but then increased significantly at 24 months of
age (Figure 9C). Sirt3 mRNA and protein expression in the liver
across development displayed similarities to its brain expression
pattern, as Sirt3 mRNA and protein levels increased dramati-
cally between E18 to PN7, then decreased by PN21 to levels
that remained similar at 3 and 24 months of age (Supplemental
Figures 5C, 6C; Supplemental Tables 12 and 13).
Within the neuronal and astrocytes cultures, while Sirt3
mRNA was present in both cell types, Sirt3 mRNA levels were
33.1 ± 0.3% higher in the neuronal cultures than in the astrocyte
cultures (p < 0.05; Figure 10A). This pattern held at the protein
level also, as SIRT3 protein was 63.5 ± 12.7% more prevalent
in extracts from the neuronal cultures compared the astrocyte
cultures (Figure 10D).
Sirt4
Sirt4 was found by quantitative RT-PCR to be the least abun-
dantly expressed member of the sirtuin family in the adult rat
brain (Figure 1). Its mRNA expression levels ranged from 0.5 to
2% of the reference gene Hprt1 throughout the different regions
of the brain, except for spinal cord, which had the highest level
of Sirt4 expression at 5% of Hprt1 (Figure 2D). This low level
of expression was also seen in the peripheral tissues, where only
the kidney expressed Sirt4 at higher levels than brain (Table 1;
Supplemental Figure 3D). At the protein level, siRNA treatment
identified one specific SIRT4 protein product with a mass of
30 kDa (Supplemental Figure 1D). SIRT4 protein expression was
detected in each of the brain regions examined at relatively sim-
ilar levels (Figure 3D). This general pattern was also seen in the
peripheral tissues, where SIRT4 protein prevalence in heart, liver,
and kidney were at levels similar to that of brain, while the spleen
and small intestine displayed lower levels of SIRT4 protein than
adult brain (Table 1; Supplemental Figure 4D).
During development, Sirt4 mRNA levels in each of the brain
regions examined were highest at the E18 stage, decreased signif-
icantly from this late embryonic level by PN2, and then remained
at fairly consistent levels between PN7 and 24 months of age
(Table 2; Figures 4D, 6D, 8D). At the protein level, no signifi-
cant differences in SIRT4 protein prevalence were noted in any
of the brain regions examined throughout development, includ-
ing the E18 time point where higher mRNA levels had been seen
(Table 2; Figures 5D, 7D, 9D). A similar pattern of mostly consis-
tent expression was also observed in the developing liver, as Sirt4
mRNA levels decreased modestly between E18 to and PN2, and
then remained fairly stable until 24 months of age (Supplemental
Figure 5D; Supplemental Table 12). Similarly, SIRT4 protein lev-
els did not significantly differ in liver from E18 to 24 months of
age (Supplemental Figure 6D; Supplemental Table 13).
Consistent with its low levels of expression levels in the brain
and peripheral tissues, Sirt4 mRNA was also the least prevalently
expressed sirtuins member in both the neuronal and astrocyte
enriched cultures, and no significant difference in Sirt4 mRNA
prevalence was observed between the neurons and astrocytes
(Figure 10A). At the protein level, SIRT4 protein expression was
also detected in each cell type, although SIRT4 protein was 41.2±
0.2% higher in the neuronal cultures compared to astrocytes (p <
0.05; Figure 10E).
Sirt5
Quantitative RT-PCR revealed that Sirt5 mRNA is expressed at
levels similar toHprt1 in whole brain homogenates, making it the
secondmost prevalently expressedmember of the sirtuin family in
the adult brain (Figure 1). However, differences in the magnitude
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FIGURE 4 | Sirtuin mRNA expression patterns during rat cortical
development. Histograms showing the mean and SEM of the
mRNA expression levels for each individual sirtuin at the indicated
stages of cortical development (E18 to 3 months) and in rats at
24 months of age. The y-axis of each histogram shows the
relative expression levels of (A) Sirt1 (B) Sirt2 (C) Sirt3 (D) Sirt4
(E) Sirt5 (F) Sirt6 (G) Sirt7 relative to the levels of the Hprt1
reference gene. Data shown are the linear conversion of delta CT
values for each sample relative to Hprt1 (n = 3 independent
subjects done in quadruplicate). Statistical comparisons for the
cortical expression levels of each sirtuin for the developmental
times shown are presented in Supplemental Table 6.
of Sirt5 expression were observed between different regions of the
adult brain. Sirt5 mRNA was significantly higher in brain stem,
hippocampus, spinal cord, and olfactory bulb than in cortex and
cerebellum (Figure 2E). At the protein level, siRNA treatment
identified one specific SIRT5 product of 35 kDa (Supplemental
Figure 1E). The adult mRNA expression profile was generally
recapitulated at the protein level, although SIRT5 protein in cere-
bellum was higher than in cortex and hippocampus (Figure 3E).
Inperipheral tissues,Sirt5mRNAexpression inkidneywas at levels
similar to brain, while all of the other peripheral tissues examined
expressed Sirt5 mRNA at levels lower than brain (Supplemental
Figure 3E). The protein profile of SIRT5 in these peripheral tissues
did not parallel its mRNA pattern, however, as SIRT5 protein was
notably higher in liver, spleen, and kidney than in whole brain,
and present at lower or non-detectable levels in small intestine
and heart (Table 1; Supplemental Figure 4E).
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FIGURE 5 | Sirtuin protein expression patterns during rat cortical
development. Representative Western blots showing the prevalence of (A)
SIRT1 (B) SIRT2 (C) SIRT3 (D) SIRT4 (E) SIRT5 (F) SIRT6 in the rat cortex at
the indicated stages of embryonic and postnatal development (n = 3
independent subjects). The corresponding GAPDH protein level for the same
blot is shown, and serves as a protein loading control. The histograms in each
panel show the densitometric mean and SEM for each specific sirtuin
normalized to its corresponding GAPDH loading control. The level of
expression for each Sirtuin in the 3-month old cortex was arbitrarily set to
100%, and different stages expressed as a percentage of this 3-month value.
Statistical comparisons for the expression levels of each sirtuin for the
developmental times shown are presented in Supplemental Table 7.
During development, Sirt5 mRNA levels decreased modestly
in the cortex and hippocampus between E18 and PN7, and then
remained at consistent levels until 24 months of age (Table 2;
Figures 4E, 6E). In the developing cerebellum, Sirt5 mRNA lev-
els decreased at 3 months of age, and this lower level remained in
tissue from 24 month old rats (Figure 8E). At the protein level,
SIRT5 immunoreactivity did not significantly differ across devel-
opment within either the cortex or hippocampus (Figures 5E,
7E), although SIRT5 protein levels in the cerebellum were higher
at 3 and 24 months when compared to levels seen at E18 or
in the perinatal stages (Table 2; Figure 9E). During liver devel-
opment, Sirt5 mRNA expression decreased between E18 and
PN2, and then remained fairly consistent until 24 months of age
(Supplemental Figure 5E; Supplemental Table 12). The pattern of
SIRT5 protein differed from this mRNA profile in liver, however,
as SIRT5 protein levels were found to increase progressively until
PN21, and then remained at similar levels at 3 and 24 months of
age (Supplemental Figure 6E; Supplemental Table 13).
Sirt5 mRNA was present at relatively high levels relative to
other Sirtuins in both the neuronal and astrocytic cultures, with
its mRNA expression being moderately but significantly higher in
neurons by 26.4 ± 0.3% than in astrocytes (Figure 10A). At the
protein level, SIRT5 prevalence was more skewed in its neuronal
preference, being 201.6 ± 60.8% higher in the neuronal cultures
than in the astrocyte cultures (p < 0.05; Figure 10F).
Sirt6
Sirt6 mRNA was found at relatively low levels in the brain by
quantitative RT-PCR, being expressed at approximately 10% the
level of the Hprt1 reference gene (Figure 1). The highest mRNA
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FIGURE 6 | Sirtuin mRNA expression patterns during rat hippocampal
development. Histograms showing the mean and SEM of the mRNA
expression levels for individual sirtuins at the indicated ages and stage of
embryonic hippocampal development. The y-axis of each histogram shows
the expression levels of (A) Sirt1 (B) Sirt2 (C) Sirt3 (D) Sirt4 (E) Sirt5 (F) Sirt6
(G) Sirt7 relative to the levels of the Hprt1 reference gene. Data shown are
based on the linear conversion of delta CT values from qRT-PCR assays for
each sample (n = 3 independent subjects done in quadruplicate). Statistical
comparisons for the hippocampal expression levels of each sirtuin for the
developmental times shown are presented in Supplemental Table 8.
expression for Sirt6 was observed in the olfactory bulb, and the
lowest expression levels were found in hippocampus and brain
stem (Figure 2F). A similar low level of mRNA expression was
also seen in peripheral tissues, with only the kidney displaying
higher Sirt6 mRNA levels than brain, and the liver and heart
showing lower expression than brain (Table 1; Supplemental
Figure 3F). At the protein level, siRNA treatment revealed two
specific SIRT6 protein products withmasses of 36 kDa and 39 kDa
(Supplemental Figure 1F). SIRT6 protein expression for each of
the isoforms was similar within the different adult brain regions
examined (Figure 3F). In adult peripheral tissues, the expression
levels of these two SIRT6 protein forms was variable, with the
36 kDa being expressed highest in the spleen, where its prevalence
was greater than in brain, whereas the intestine expressed low or
non-detectable levels of this 36 kDa form (Table 1; Supplemental
Figure 4F). In contrast, the 39 kDa form was expressed at levels
similar to brain in heart and intestine, while liver displayed low to
non-detectable levels of this 39 kDa SIRT6 form.
In the developing brain, Sirt6 mRNA levels were highest in
the cortex, hippocampus, and cerebellum at the E18 stage, and
then decreased to levels at PN7 that were maintained at 24
months (Table 2; Figures 4F, 6F, 8F). Sirt6 mRNA expression
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FIGURE 7 | Sirtuin protein expression patterns during rat hippocampal
development. Representative Western blots showing (A) SIRT1 (B) SIRT2
(C) SIRT3 (D) SIRT4 (E) SIRT5 (F) SIRT6 protein levels in rat hippocampus at
the indicated embryonic or postnatal stages (n = 3 independent subjects).
The corresponding GAPDH protein level for the same blot is shown, and
serves as a protein loading control. The histograms show the densitometric
mean and SEM for each specific sirtuin normalized to its corresponding
GAPDH loading control, with the 3-month value arbitrarily set as 100%.
Statistical comparisons for the expression levels of each sirtuin for the
developmental times shown are presented in Supplemental Table 9.
in the developing liver similarly decreased during early perina-
tal development from its late embryonic level, and remained at
similar levels until 24 months of age (Supplemental Figure 5F;
Supplemental Table 12). At the protein level, the different forms
of expressed SIRT6 protein displayed region-specific differences
in expression. Throughout cortical and hippocampal develop-
ment, the prevalence of the 36 kDa product decreased from E18
to PN21, and then remained at similar levels in these respec-
tive tissues at 3 and 24 months of age. This was not the case
for the 39 kDa SIRT6 protein product, though, as its preva-
lence remained constant throughout cortical and hippocampal
development (Table 2; Figures 5F, 7F). In the developing cere-
bellum, the 36 kDa SIRT6 product was found at similar levels
throughout development, while the 39 kDa form increased in
prevalence between E18 and PN7, and then remained at fairly
consistent levels until 24 months of age (Table 2; Figure 9F). In
the developing liver, the 36 kDa SIRT6 protein form was found
at consistent levels throughout development, whereas the preva-
lence of the 39 kDa product was at low or background levels for
each of the developmental stages examined (Supplemental Figure
6F; Supplemental Table 13).
In the neuronal and astrocyte-enriched culture extracts, Sirt6
mRNA was detected in both cell lineages, and at similar levels
(Figure 10A). At the protein level, SIRT6 immunoreactivity was
also found in both the neuronal and astrocyte-enriched cultures,
although both the 36 kDa and the 39 kDa protein products dis-
played preferential expression in one cell type. The prevalence
of the 36 kDa SIRT6 product was 191.6 ± 63.8% higher in the
neuronal cultures than in the astrocytes (p < 0.05; Figure 10G),
while the prevalence of the 39 kDa SIRT6 protein form was
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FIGURE 8 | Sirtuin mRNA expression patterns during rat cerebellum
development. Histograms showing the mean and SEM of the mRNA
expression levels for individual sirtuins in the cerebellum at the indicated
ages and stage of embryonic development. The y-axis of each histogram
shows the expression levels of (A) Sirt1 (B) Sirt2 (C) Sirt3 (D) Sirt4 (E) Sirt5
(F) Sirt6 (G) Sirt7 relative to the levels of the Hprt1 reference gene. Data
shown depict the linear conversion of delta CT values from qRT-PCR assays
for each sample (n = 3 independent subjects done in quadruplicate).
Statistical comparisons for the cerebellar expression levels of each sirtuin for
the developmental times shown are presented in Supplemental Table 10.
32.8 ± 9.5% higher in the astrocyte cultures compared to the
neurons (p < 0.05; Figure 10G).
Sirt7
Quantitative RT-PCR revealed that Sirt7 is also expressed at low
levels in the adult brain relative to other sirtuin family members,
being present at roughly 5% the levels of theHprt1 reference gene
(Figure 1). Within the different regions of the adult brain exam-
ined, no significant differences in Sirt7 mRNA expression was
detected (Figure 2G). Interestingly, and in contrast to the other
sirtuin family members, Sirt7 mRNA expression was highest in
the small intestine (Table 1; Supplemental Figure 3G), where its
expression levels were about 10-fold higher than its mRNA lev-
els in brain. Although lower than in small intestine, both the
spleen and kidney also showed significantly higher Sirt7 mRNA
expression levels than the brain.
During cortical and hippocampal development, Sirt7 mRNA
levels decreased between E18 and PN2, but then remained
at similar levels throughout the remaining time points exam-
ined (Table 2; Figures 4G, 6G). In the cerebellum, Sirt7 mRNA
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FIGURE 9 | Sirtuin protein expression patterns during rat cerebellum
development. Representative Western blots showing (A) SIRT1 (B) SIRT2
(C) SIRT3 (D) SIRT4 (E) SIRT5 (F) SIRT6 protein levels in rat cerebellum at
the indicated embryonic or postnatal stages (n = 3 independent subjects).
The corresponding GAPDH protein level for the same blot is shown, and
serves as a protein loading control. The histograms show the densitometric
mean and SEM for each specific sirtuin normalized to its corresponding
GAPDH control, with the 3-month value arbitrarily set as 100%. Statistical
comparisons for the expression levels of each sirtuin for the developmental
times shown are presented in Supplemental Table 11.
levels remained at relatively similar levels throughout perinatal
development, as well as in the adult and 24 month old brain
(Table 2; Figure 8G). Across liver development, Sirt7 mRNA lev-
els decreased modestly from E18 to PN21, and then remained
at similar levels at 3 and 24 months (Supplemental Figure 5G;
Supplemental Table 12). In the neuronal and astrocyte-enriched
culture extracts, Sirt7 mRNA was detected in both lineages,
with its expression in astrocytes being 60.1 ± 0.1% higher than
in neuronal cultures than in astrocytes (p < 0.05; Figure 10A).
SIRT7 protein expression patterns could not be determined
in this study, as we failed to identify a SIRT7 antibody that
yielded a product that could be suppressed by Sirt7 targeted
siRNA treatment (see Materials and Methods and Supplemental
Figure 1G).
DISCUSSION
In this study we assessed the expression patterns of seven sir-
tuin family members in specific regions of the developing, adult,
and aged rat brain (Table 2). Four principle findings emerge from
our study. First, although each of the sirtuin family members
is expressed within the adult and developing rat brain, there
is considerable variability in the magnitude of mRNA expres-
sion between each of the individual sirtuins, with Sirt2 being the
most prominently expressed and Sirt4 being the least expressed.
Second, although there is some overlap between specific mem-
bers, individual sirtuin family members display a unique pattern
of temporal and spatial expression within the adult and devel-
oping brain. Third, specific members of the sirtuin family display
preferential or even selective cell type expression patterns between
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FIGURE 10 | Sirtuin mRNA expression in mature rat astrocytes and
neurons. (A) Histogram showing the mean and SEM of Sirt1-7 mRNA
expression levels in primary cultures of astrocytes (gray bars) and neurons
(black bars). The y-axis shows the relative mRNA expression levels relative to
the endogenous housekeeping Hprt1 reference gene in each culture
condition. Data shown depict the linear conversion of delta CT values from
qRT-PCR assays for each sample (n = 3 independent subjects done in
(Continued)
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FIGURE 10 | Continued
quadruplicate). Asterisks denote significant differences in the relative
expression of the specific sirtuin between astrocyte and neuronal cultures
(p < 0.05, Student’s t-test). (B–G) Representative Western blots showing the
relative immunoreactive levels of (B) SIRT1, (C) SIRT2 (D) SIRT3 (E) SIRT4
(F) SIRT5 (G) SIRT6 in cultured astrocytes and neurons. The histograms
show the mean and SEM of the densitometric band intensity for each sirtuin
normalized to its corresponding β-actin levels. Asterisks denote significant
differences in expression levels for the indicated sirtuin between the neuronal
and astrocyte cultures (n = 3, p < 0.05, student’s t-test).
neurons and astrocytes at the mRNA and protein levels. Fourth,
there is notable discordance between the mRNA and protein
expression patterns for Sirt2, indicating that its protein expression
pattern is likely regulated by post-transcriptional mechanisms.
Collectively, these results reveal a contrasting expression pat-
tern for the seven sirtuin family members in the developing and
adult brain, and suggest that metabolic processes and/or oxida-
tive defense systems within different regions of the brain, and
potentially within specific neural cell types, may be differentially
regulated by specific combinations of sirtuins.
Although previous studies have indicated different sirtuins are
expressed within the brain (Ford et al., 2006; Mostoslavsky et al.,
2006; Li et al., 2007; Lombard et al., 2007; Ramadori et al., 2008;
Nakagawa et al., 2009), our results indicate that there is consid-
erable divergence amongst the family members in their spatial
expression patterns, in their developmental profile of expression,
and in the magnitude of their mRNA abundance within specific
brain regions. Although none of the adult brain regions we exam-
ined was devoid of expressing any sirtuin member, the three most
prevalently expressed sirtuins within each brain region were Sirt2,
Sirt3, and Sirt5. This general pattern was also recapitulated in the
peripheral tissues we examined, although in some peripheral tis-
sues Sirt7 mRNA was more prevalent that Sirt5 or Sirt3. In fact,
Sirt7 mRNA levels were significantly higher in peripheral tissues
than Sirt7 mRNA levels in any region of the adult brain we tested.
This differential Sirt7 mRNA expression pattern may indicate a
more prominent role for Sirt7 in tissues with high cell prolifera-
tion rates as suggested previously (Ford et al., 2006), as compared
to its role within the largely post-mitotic brain.
During development, Sirt1, Sirt6, and Sirt7 mRNA levels were
significantly higher in the late embryonic and early postna-
tal regions of the brain than in the corresponding adult brain
regions. Only Sirt4 displayed lower mRNA levels than Sirt1, Sirt6,
and Sirt7 in these brain regions during early perinatal devel-
opment or in the adult stage. The relatively low mRNA levels
observed for Sirt1, as well as for Sirt6 and Sirt7, in brain regions
from 3 and 24 month old rats relative to their expression levels
in the late embryonic and early postnatal times were somewhat
surprising, as Sirt1 has been strongly implicated as a neuropro-
tective factor in models of Huntington’s disease (Jeong et al.,
2011), Multiple sclerosis (Shindler et al., 2007; Khan et al., 2014),
stroke (Yan et al., 2013) and Alzheimer’s disease (Qin et al., 2006).
However, low basal expression levels could potentially be advan-
tageous for these sirtuins in the brain, as SIRT1 levels have been
shown to increase significantly in different cultured cell lines
when they are exposed to conditions of energy/nutrient stress
(Kanfi et al., 2008; Chen et al., 2011; Li et al., 2013). Similarly,
SIRT6 and SIRT7 have been implicated in the maintenance of
DNA integrity, and in DNA repair following damage (Ford et al.,
2006; Cardus et al., 2013), which is often a consequence of
increased cellular stress. Therefore, the relatively lower levels of
Sirt1, Sirt6, and Sirt7 present in the adult brain under nor-
mal conditions may allow for their pronounced induction under
pathophysiological conditions to facilitate a beneficial compen-
satory response in times of need. It is worth noting that neither
the mRNA levels or protein prevalence of either SIRT1 or SIRT6
in the 24 month old cortex or hippocampus differed from their
respective levels at 3 months of age, suggesting that aging alone
does not alter the expression of these sirtuins. While this suggests
the lack of an endogenous age-related compensatory response
to aging, these results do confirm the expression of each sirtuin
in the aged brain, which therefore validates their pharmacolog-
ical targeting for age-related conditions. Indeed, brain-specific
SIRT1 over-expressing transgenic mice show significant life span
extensions (Satoh et al., 2013), suggesting enhancing SIRT1 activ-
ity pharmacologically in the brain may yield a similar effect.
Likewise, the global over-expression of SIRT6 in transgenic mice
similarly extended life span (Kanfi et al., 2012), suggesting SIRT6
may also be a rationale target for drug development. In our
study, analysis of SIRT6 protein expression revealed two prod-
ucts at 36 kDa and 39 kDa, which comports with a recent study
examining how preterm labor affects SIRT6 expression that also
reported the presence of two distinct SIRT6 products (Lim et al.,
2013). Interestingly, we show that these distinct SIRT6 forms
displayed somewhat opposing expression patterns during brain
development: while the 36 kDa product decreased during perina-
tal development, the 39 kDa product increased as the animal aged.
While the reason for the divergent expression pattern remains
unknown, these results indicate that an examination of the role
played by each in temporal brain development and aging is
warranted.
Analysis of the astrocytic and neuronal expression patterns of
the predominantly nuclear residing Sirt1, Sirt6, and Sirt7 sirtuins
revealed that while each sirtuin is expressed in these two neu-
ral cell lineages, their relative expression levels are not equivalent
between the two cell types. At the mRNA level, Sirt1, Sirt6, and
Sirt7 displayed modestly (approximately 2-fold) higher expres-
sion in astrocytes than in neurons relative to the reference gene
Hprt1. At the protein level, this pattern of more predominant
astrocyte expression was not recapitulated by SIRT1, whose pro-
tein prevalence was found to be significantly higher in neurons
than in astrocytes. This differential expression profile of Sirt1
mRNA and protein between cultured astrocytes and neurons sug-
gests that post-transcriptional factors may play a role in establish-
ing SIRT1 protein expression patterns in these specific cell types.
Importantly, these results also indicate that glial cells should
be considered as potential mediators of neuroprotective actions
associated with SIRT1-activating drugs (Shindler et al., 2007;
Khan et al., 2014). Somewhat surprisingly, SIRT6 protein expres-
sion was found to display isoform-specific preferences between
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neurons and astrocytes. This could indicate the two forms influ-
ence specific cell types in the brain in different or specific
manners. Favero et al. (2014) recently reported SIRT6 immunore-
activity within the nucleus of cortical neurons in mouse brain.
Although this study did not resolve specific forms of SIRT6, or
explicitly examine SIRT6 expression in astrocytes, the presence of
SIRT6 immunoreactivity in neurons is consistent with our results.
In this regard, it is of interest to note that the selective ablation
of SIRT6 from neurons in mice results in an adult-onset obesity
(Schwer et al., 2010), while liver-specific deletion of Sirt6 in mice
results in a “fatty liver” phenotype (Kim et al., 2010). Our results
indicate that the 36 kDa product is the form most predominately
expressed in neurons, and is the only form reliably detected in the
developing and adult liver. By extrapolation, this would suggest
the loss of the 36 kDa form may be predominantly responsible
for the observed phenotypes in these respective studies. At the
least, our results confirm that both SIRT1 and SIRT6 proteins are
expressed in varying levels in both neurons and astrocytes which
therefore indicates drugs designed to enhance the catalytic activ-
ity of either SIRT1 or SIRT6 should elicit effects within both of
these cell types—but potentially with differing cell-selective effi-
cacies depending on the sirtuin, or the SIRT6 form, that is being
pharmacologically targeted.
In contrast to the relative low expression levels of the nuclear
sirtuins, the mRNA expression levels of the cytosolic-nuclear sir-
tuin Sirt2 were robust. High levels of Sirt2 mRNA were detected
ubiquitously throughout the different regions of the adult and
developing brain examined, and in each of the peripheral tis-
sues investigated. These results are consistent with a recent study
showing Sirt2mRNA is expressed at high levels in the human cor-
tex (Korner et al., 2013), and illustrate Sirt2 mRNA is expressed
at higher levels than any of the other sirtuins in the adult or
developing rat brain, peripheral tissues, and also in extracts from
both the neuronal and astrocyte-enriched cultures, respectively.
However, there is a pronounced disconnect between the high
levels of Sirt2 mRNA expression in the embryonic and early post-
natal brain, and the low to non-detectable amounts of SIRT2
protein detected by immunoblot in the same tissues. While iso-
forms of SIRT2 have been reported (Maxwell et al., 2011), the
SIRT2 antibody we employed targets a carboxyl region of SIRT2
that is common to the different isoforms that have been character-
ized to date, suggesting that the differential expression we detect
does not arise from the antibody we used missing an isoform-
specific product lacking this epitope. This, together with the cell
lineage expression results discussed below, raises the possibil-
ity that post-transcriptional mechanisms may strongly influence
the expression of SIRT2 protein in the developing brain and in
specific cell contexts.
There has been controversy to date over which types of neu-
ral cells express Sirt2 in the brain. Using antisense mRNA in
situ hybridization, as well as anti-SIRT2 immunohistochemisty,
Li et al. (2007) reported strong SIRT2 expression in oligodendro-
cytes, but minimal to non-detectable Sirt2 mRNA expression in
neurons or astrocytes. In contrast, Maxwell et al. (2011) reported
robust SIRT2 protein expression in neurons, modest expression
in oligodendrocytes, and low to undetectable SIRT2 expression in
astrocytes through immunohistochemical analysis. Imaoka et al.
(2012) reported strong SIRT2 immunohistochemical expression
in astrocytes of glioblastoma, astrocytoma, and normal human
brain samples. The reasons for the discordance is not clear, but
one concern with immunohistochemical studies is whether the
employed antibodies label non-specific proteins in addition to
their primary intended target that would cloud data interpre-
tation. Our study assessed SIRT2 protein (as well as each of
the other Sirtuin family members) by Western blotting rather
than immunocytochemistry, which allowed us to focus selec-
tively on an immunoreactive product that could be significantly
and selectively suppressed by Sirt2 targeted siRNA treatment
(Supplemental Figure 1B). When combined with quantitative
PCR outcomes, these immunoblot results reveal an interest-
ing phenomenon: although Sirt2 mRNA is clearly detected at
high levels in both neuronal and astrocyte enriched cultures,
SIRT2 immunoreactive protein is detected at robust levels only
in the astrocyte-enriched culture extracts, with minimal or no
protein detected in extracts from the neuronal cultures. While
we did not examine oligodendrocytes specifically, our astrocyte-
enriched cultures displayed only minor immunoreactivity for the
oligodendrocyte-specific marker Ng2 relative to whole brain sam-
ples, and Ng2 was not detected in the neuronal-enriched cultures
(Supplemental Figure 7). This argues against the SIRT2 pro-
tein we detect stemming from a contaminating oligodendrocytes
presence in the enriched cultures. Furthermore, the developmen-
tal expression pattern for SIRT2 in cortex showed similarity to
that of the GFAP (Supplemental Figure 8), indicating that the
appearance of SIRT2 is largely coincident with a wave of astro-
genesis in the developing postnatal cortex. A similar coincident
pattern of expression was observed for the 39 kDa form of SIRT6.
This coincident expression raises the possibility that the expres-
sion patterns for SIRT2 and SIRT6 in the developing brain could
relate to increases in astrocyte prevalence. However, given that
pronounced Sirt2 mRNA expression was detected in both the
neuronal and astrocyte enriched cultures, the relative absence of
SIRT2 protein in neurons suggests that SIRT2 protein expression
must be negatively regulated in neurons by post-transcriptional
mechanisms that either prevent protein from being generated
from expressed transcripts, or that rapidly destabilize and degrade
SIRT2 protein in cultured neurons upon its synthesis.
The expression patterns of the mitochondrial sirtuins Sirt3,
Sirt4, and Sirt5 displayed a wide range of spatial and temporal
divergence in the developing and adult brain, as well as con-
siderable differences in magnitude of expression. Sirt5 and Sirt3
mRNA levels were found to be the second and third most abun-
dant sirtuin transcripts in the developing and adult brain, in both
the neuronal and astrocyte specific cultures, and in most of the
peripheral tissues examined, respectively. The relatively higher
expression levels observed for Sirt5 and Sirt3 mRNAs were not
unexpected, as these sirtuins regulate mitochondrial homeosta-
sis, metabolism and reactive oxygen species genesis in multiple
cell types (Bell et al., 2011; reviewed in He et al., 2012; Webster
et al., 2012). We found no evidence for significantly different
expression levels of SIRT3, SIRT4, or SIRT5 protein in the brain
tissues we assessed from rats at 24 months compared to 3 month
of age, indicating an apparent lack of age-associated decrease
in the brain expression of these mitochondrial sirtuins. This
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result contrasts with those of Zeng et al. (2014), who reported
decreased SIRT3 protein levels in the aged rat auditory cortex,
and Di Loreto et al. (2014) who also reported a decrease in SIRT3
protein levels in the aged mouse cortex relative to young adult
under conditions of acute food and water deprivation. The reason
for these differing results is unclear, but could relate to cortical
subfield specific changes in SIRT3, and/or the influence of dif-
ferent stress conditions presented to the subjects in the studies.
Because mitochondrial dysfunction is heavily implicated in aging
(reviewed in Lee andWei, 2012) and SIRT3 modulates mitochon-
drial metabolism and anti-oxidative defense systems (reviewed
in Kincaid and Bossy-Wetzel, 2013), the preserved prevalence of
SIRT3, as well as SIRT4 and SIRT5, in the aged brain confirm that
drugs selectively targeting any of these sirtuins would be expected
to exert effects at later stages of aging. Further, as our results indi-
cate each of these sirtuins are expressed in both neurons and
astrocytes, the same drugs would likely affect both neural cell
types. Interestingly, although SIRT3 protein has been reported
to be expressed two predominant forms: a 45 kDa product cor-
responding in mass to its precursor form, and a 28 kDa product
corresponding to its form following import into mitochondria
after processing by mitochondrial processing peptidase (Onyango
et al., 2002), we could only verify the 28 kDa product recog-
nized with the antibody we employed as originating from Sirt3
(Supplemental Figure 1C). It is not clear whether a 45 kDa SIRT3
product is also present in brain that is masked in the SIRT3-null
mouse brain by a cross-reactive co-migrating non-specific pro-
tein. As such, we only report the protein expression profile for the
processed form of SIRT3, which could conceivably differ from the
45 kDa form that has been detected in the nucleus (Iwahara et al.,
2012). Additional studies will be required to resolve this possi-
bility. Finally, in contrast to the relatively high expression levels
observed for Sirt3 and Sirt5, Sirt4was generally the least expressed
member of the sirtuin family in all of the adult tissues and cell
types examined. The notably higher level of Sirt4 mRNA expres-
sion in late embryonic stage cortex and hippocampus compared
to perinatal or adult brain regions suggest Sirt4 may be more
prominently expressed during embryogenesis, and that a closer
examination of Sirt4 during embryonic brain development may
be warranted.
In sum, this study illustrates sirtuin family members display
differential expression patterns within the developing and adult
brain at both the mRNA and protein levels, with specific fam-
ily members displaying preferential expression in either astrocytes
or neurons. Our results indicate that mRNA for each of the seven
sirtuins is expressed in the brain throughout development. In all
brain regions examined during development, Sirt2 was the most
prevalently expressed sirtuin, and Sirt4 was the least expressed
member of the family. No significant decreases in the expression
of any sirtuin member were observed in any brain region between
the 24 month old and 3 month old rats. However, the mRNA
expression pattern for specific sirtuins did not always parallel its
corresponding protein expression pattern. This was most evident
for SIRT2, where protein expression was largely absent at early
developmental stages despite the presence of pronounced mRNA
expression. This differential expression was also noted in cell type
specificity, where Sirt2mRNAwas detected in both astrocytes and
neurons whereas SIRT2 protein was selectively observed in astro-
cytes. Sirt5 also displayed similar differential cell type expression,
as SIRT5 protein was preferentially observed in neurons despite its
mRNA being present in both astrocytes and neurons. Collectively,
these results add to our knowledge of the regulation of sirtuin
expression within the brain at different developmental stages, and
provide information on which specific sirtuins could potentially
be targeted pharmacologically in the brain at times ranging from
perinatal development to 24 months of age. These data also pro-
vide evidence that specific sirtuins could potentially be targeted
to achieve cell-type preferential effects within the brain.
ACKNOWLEDGMENTS
The authors declare no conflict of interest with this study. We
wish to thank Richard Logan and Jamie Fong for technical assis-
tance, Dr. Linda Mills for critical review of this manuscript, Alex
Laliberte for assistance with real-time PCR, and Peter Darmos
for editing assistance. Elena Sidorova-Darmos is the recipient of
an Ontario Graduate Scholarship, an Ontario Heart & Stroke
Foundation Scholarship, a Peterborough K.M. Hunter Graduate
Scholarship and a Norman Stuart Robertson Fellowship; Melanie
Ratnam received fellowship support from the Canadian Institutes
of Health Research, and an Ontario Graduate Scholarship;
Natalya Shulyakova received fellowship support from the Natural
Sciences and Engineering Research Council of Canada. This
work was supported by an operating grant awarded to James
H. Eubanks by the Heart and Stroke Foundation of Canada
(NA-7041).
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: http://www.frontiersin.org/journal/10.3389/fnagi.2014.
00333/abstract
REFERENCES
Ahuja, N., Schwer, B., Carobbio, S., Waltregny, D., North, B. J., Castronovo,
V., et al. (2007). Regulation of insulin secretion by SIRT4, a mito-
chondrial ADP-ribosyltransferase. J. Biol. Chem. 282, 33583–33592. doi:
10.1074/jbc.M705488200
Bell, E. L., Emerling, B. M., Ricoult, S. J., and Guarente, L. (2011). SirT3 suppresses
hypoxia inducible factor 1alpha and tumor growth by inhibiting mitochondrial
ROS production. Oncogene 30, 2986–2996. doi: 10.1038/onc.2011.37
Braidy, N., Guillemin, G. J., Mansour, H., Chan-Ling, T., Poljak, A., and Grant,
R. (2011). Age related changes in NAD+ metabolism oxidative stress and Sirt1
activity in wistar rats. PLoS ONE 6:e19194. doi: 10.1371/journal.pone.0019194
Cardus, A., Uryga, A. K., Walters, G., and Erusalimsky, J. D. (2013). SIRT6 pro-
tects human endothelial cells from DNA damage, telomere dysfunction, and
senescence. Cardiovasc. Res. 97, 571–579. doi: 10.1093/cvr/cvs352
Chen, R., Dioum, E. M., Hogg, R. T., Gerard, R. D., and Garcia, J. A. (2011).
Hypoxia increases sirtuin 1 expression in a hypoxia-inducible factor-dependent
manner. J. Biol. Chem. 286, 13869–13878. doi: 10.1074/jbc.M110.175414
Di Loreto, S., Falone, S., D’Alessandro, A., Santini, S. Jr., Sebastiani, P., Cacchio, M.,
et al. (2014). Regular andmoderate exercise initiated inmiddle age prevents age-
related amyloidogenesis and preserves synaptic and neuroprotective signaling in
mouse brain cortex. Exp. Gerontol. 57, 57–65. doi: 10.1016/j.exger.2014.05.006
Eaton, S. L., Roche, S. L., Llavero Hurtado, M., Oldknow, K. J., Farquharson, C.,
Gillingwater, T. H., et al. (2013). Total protein analysis as a reliable loading
control for quantitative fluorescent Western blotting. PLoS ONE 8:e72457. doi:
10.1371/journal.pone.0072457
Favero, G., Rezzani, R., and Rodella, L. F. (2014). Sirtuin 6 nuclear localization at
cortical brain level of young diabetic mice: an immunohistochemical study. Acta
Histochem. 116, 272–277. doi: 10.1016/j.acthis.2013.08.006
Frontiers in Aging Neuroscience www.frontiersin.org December 2014 | Volume 6 | Article 333 | 18
Sidorova-Darmos et al. Spatial and temporal expression of sirtuins in brain
Fischer, M., Skowron, M., and Berthold, F. (2005). Reliable transcript quantifica-
tion by real-time reverse transcriptase-polymerase chain reaction in primary
neuroblastoma using normalization to averaged expression levels of the con-
trol genes HPRT1 and SDHA. J. Mol. Diagn. 7, 89–96. doi: 10.1016/S1525-
1578(10)60013-X
Ford, E., Voit, R., Liszt, G., Magin, C., Grummt, I., and Guarente, L. (2006).
Mammalian Sir2 homolog SIRT7 is an activator of RNA polymerase I transcrip-
tion. Genes Dev. 20, 1075–1080. doi: 10.1101/gad.1399706
Franco-Montoya, M. L., Boucherat, O., Thibault, C., Chailley-Heu, B., Incitti, R.,
Delacourt, C., et al. (2011). Profiling target genes of FGF18 in the postnatal
mouse lung: possible relevance for alveolar development. Physiol. Genomics 43,
1226–1240. doi: 10.1152/physiolgenomics.00034.2011
Frye, R. A. (2000). Phylogenetic classification of prokaryotic and eukary-
otic Sir2-like proteins. Biochem. Biophys. Res. Commun. 273, 793–798. doi:
10.1006/bbrc.2000.3000
Greiss, S., and Gartner, A. (2009). Sirtuin/Sir2 phylogeny, evolutionary considera-
tions and structural conservation. Mol. Cells 28, 407–415. doi: 10.1007/s10059-
009-0169-x
Guarente, L. (2013). Calorie restriction and sirtuins revisited. Genes Dev. 27,
2072–2085. doi: 10.1101/gad.227439.113
He, W., Newman, J. C., Wang, M. Z., Ho, L., and Verdin, E. (2012).
Mitochondrial sirtuins: regulators of protein acylation and metabolism.
Trends Endocrinol. Metab. 23, 467–476. doi: 10.1016/j.tem.2012.
07.004
Herculano-Houzel, S. (2011). Scaling of brain metabolism with a fixed
energy budget per neuron: implications for neuronal activity, plas-
ticity and evolution. PLoS ONE 6:e17514. doi: 10.1371/journal.pone.
0017514
Houtkooper, R. H., Pirinen, E., and Auwerx, J. (2012). Sirtuins as regulators
of metabolism and healthspan. Nat. Rev. Mol. Cell. Biol. 13, 225–238. doi:
10.1038/nrm3293
Imaoka, N., Hiratsuka, M., Osaki, M., Kamitani, H., Kambe, A., Fukuoka, J.,
et al. (2012). Prognostic significance of sirtuin 2 protein nuclear localiza-
tion in glioma: an immunohistochemical study. Oncol. Rep. 28, 923–930. doi:
10.3892/or.2012.1872
Iwahara, T., Bonasio, R., Narendra, V., and Reinberg, D. (2012). SIRT3 functions in
the nucleus in the control of stress-related gene expression. Mol. Cell. Biol. 32,
5022–5034. doi: 10.1128/MCB.00822-12
Jeong, H., Cohen, D. E., Cui, L., Supinski, A., Savas, J. N., Mazzulli, J. R., et al.
(2011). Sirt1 mediates neuroprotection from mutant huntingtin by activation
of the TORC1 and CREB transcriptional pathway. Nat. Med. 18, 159–165. doi:
10.1038/nm.2559
Jin, Q., Yan, T., Ge, X., Sun, C., Shi, X., and Zhai, Q. (2007). Cytoplasm-
localized SIRT1 enhances apoptosis. J. Cell. Physiol. 1, 88–97. doi: 10.1002/
jcp.21091
Kanfi, Y., Naiman, S., Amir, G., Peshti, V., Zinman, G., Nahum, L., et al. (2012).
The sirtuin SIRT6 regulates lifespan in male mice. Nature 483, 218–221. doi:
10.1038/nature10815
Kanfi, Y., Peshti, V., Gozlan, Y. M., Rathaus, M., Gil, R., and Cohen, H. Y. (2008).
Regulation of SIRT1 protein levels by nutrient availability. FEBS Lett. 582,
2417–2423. doi: 10.1016/j.febslet.2008.06.005
Khan, R. S., Dine, K., Das Sarma, J., and Shindler, K. S. (2014). SIRT1 Activating
compounds reduce oxidative stress mediated neuronal loss in viral induced
CNS demyelinating disease.Acta Neuropathol. Commun. 2:3. doi: 10.1186/2051-
5960-2-3
Kim, H. S., Xiao, C., Wang, R. H., Lahusen, T., Xu, X., Vassilopoulos, A., et al.
(2010). Hepatic-specific disruption of SIRT6 in mice results in fatty liver for-
mation due to enhanced glycolysis and triglyceride synthesis. Cell Metab. 12,
224–236. doi: 10.1016/j.cmet.2010.06.009
Kincaid, B., and Bossy-Wetzel, E. (2013). Forever young: SIRT3 a shield against
mitochondrial meltdown, aging, and neurodegeneration. Front. Aging Neurosci.
5:48. doi: 10.3389/fnagi.2013.00048
Korner, S., Boselt, S., Thau, N., Rath, K. J., Dengler, R., and Petri, S.
(2013). Differential sirtuin expression patterns in amyotrophic lateral scle-
rosis (ALS) postmortem tissue: neuroprotective or neurotoxic properties
of sirtuins in ALS? Neurodegener. Dis. 11, 141–152. doi: 10.1159/000
338048
Lee, H. C., and Wei, Y. H. (2012). Mitochondria and aging. Adv. Exp. Med. Biol.
942, 311–327. doi: 10.1007/978-94-007-2869-1_14
Li, W., Zhang, B., Tang, J., Cao, Q., Wu, Y., Wu, C., et al. (2007). Sirtuin 2, a mam-
malian homolog of yeast silent information regulator-2 longevity regulator, is an
oligodendroglial protein that decelerates cell differentiation through deacetylat-
ing alpha-tubulin. J. Neurosci. 27, 2606–2616. doi: 10.1523/JNEUROSCI.4181-
06.2007
Li, Y. B., Zhong, Z. F., Chen, M. W., Bao, J. L., Wu, G. S., Zhang, Q., et al.
(2013). Bisdemethoxycurcumin Increases Sirt1 to Antagonize t-BHP-Induced
Premature Senescence in WI38 Fibroblast Cells. Evid. Based Complement.
Alternat. Med. 2013:851714. doi: 10.1155/2013/851714
Lim, R., Barker, G., and Lappas, M. (2013). SIRT6 is decreased with preterm
labor and regulates key terminal effector pathways of human labor in fetal
membranes. Biol. Reprod. 88, 17. doi: 10.1095/biolreprod.112.105163
Lombard, D. B., Alt, F. W., Cheng, H. L., Bunkenborg, J., Streeper, R. S.,
Mostoslavsky, R., et al. (2007). Mammalian Sir2 homolog SIRT3 regulates
global mitochondrial lysine acetylation. Mol. Cell. Biol. 27, 8807–8814. doi:
10.1128/MCB.01636-07
Maxwell, M. M., Tomkinson, E. M., Nobles, J., Wizeman, J. W., Amore, A. M.,
Quinti, L., et al. (2011). The Sirtuin 2 microtubule deacetylase is an abun-
dant neuronal protein that accumulates in the aging CNS. Hum. Mol. Genet.
20, 3986–3996. doi: 10.1093/hmg/ddr326
Michan, S., and Sinclair, D. (2007). Sirtuins in mammals: insights into their
biological function. Biochem. J. 404, 1–13. doi: 10.1042/BJ20070140
Michishita, E., Park, J. Y., Burneskis, J. M., Barrett, J. C., and Horikawa, I. (2005).
Evolutionarily conserved and nonconserved cellular localizations and functions
of human SIRT proteins. Mol. Biol. Cell 16, 4623–4635. doi: 10.1091/mbc.E05-
01-0033
Mostoslavsky, R., Chua, K. F., Lombard, D. B., Pang, W. W., Fischer, M. R., Gellon,
L., et al. (2006). Genomic instability and aging-like phenotype in the absence of
mammalian SIRT6. Cell 124, 315–329. doi: 10.1016/j.cell.2005.11.044
Murta, D., Batista, M., Silva, E., Trindade, A., Henrique, D., Duarte, A., et al.
(2013). Dynamics of Notch pathway expression during mouse testis post-natal
development and along the spermatogenic cycle. PLoS ONE 8:e72767. doi:
10.1371/journal.pone.0072767
Nakagawa, T., Lomb, D. J., Haigis, M. C., and Guarente, L. (2009). SIRT5
Deacetylates carbamoyl phosphate synthetase 1 and regulates the urea cycle.Cell
137, 560–570. doi: 10.1016/j.cell.2009.02.026
North, B. J., Marshall, B. L., Borra, M. T., Denu, J. M., and Verdin, E. (2003). The
human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase. Mol.
Cell 11, 437–444. doi: 10.1016/S1097-2765(03)00038-8
Onyango, P., Celic, I., McCaffery, J. M., Boeke, J. D., and Feinberg, A. P. (2002).
SIRT3, a human SIR2 homologue, is an NAD-dependent deacetylase local-
ized to mitochondria. Proc. Natl. Acad. Sci. U.S.A. 99, 13653–13658. doi:
10.1073/pnas.222538099
Pantazi, E., Zaouali, M. A., Bejaoui, M., Folch-Puy, E., Ben Abdennebi, H., and
Rosello-Catafau, J. (2013). Role of sirtuins in ischemia-reperfusion injury.
World J. Gastroenterol. 19, 7594–7602. doi: 10.3748/wjg.v19.i43.7594
Pillai, J. B., Isbatan, A., Imai, S., and Gupta, M. P. (2005). Poly(ADP-ribose)
polymerase-1-dependent cardiac myocyte cell death during heart failure is
mediated by NAD+ depletion and reduced Sir2alpha deacetylase activity. J. Biol.
Chem. 280, 43121–43130. doi: 10.1074/jbc.M506162200
Qin, W., Yang, T., Ho, L., Zhao, Z., Wang, J., Chen, L., et al. (2006). Neuronal SIRT1
activation as a novel mechanism underlying the prevention of Alzheimer disease
amyloid neuropathology by calorie restriction. J. Biol. Chem. 281, 21745–21754.
doi: 10.1074/jbc.M602909200
Rajendran, R., Garva, R., Krstic-Demonacos, M., and Demonacos, C. (2011).
Sirtuins: molecular traffic lights in the crossroad of oxidative stress, chro-
matin remodeling, and transcription. J. Biomed. Biotechnol. 2011:368276. doi:
10.1155/2011/368276
Ramadori, G., Lee, C. E., Bookout, A. L., Lee, S., Williams, K. W., Anderson, J.,
et al. (2008). Brain SIRT1: anatomical distribution and regulation by energy
availability. J. Neurosci. 28, 9989–9996. doi: 10.1523/JNEUROSCI.3257-08.2008
Satoh, A., Brace, C. S., Rensing, N., Cliften, P., Wozniak, D. F., and Herzog, E. D.
(2013). Sirt1 extends life span and delays aging in mice through the regula-
tion of Nk2 homeobox 1 in the DMH and LH. Cell Metab. 18, 416–430. doi:
10.1016/j.cmet.2013.07.013
Schwer, B., Schumacher, B., Lombard, D. B., Xiao, C., Kurtev, M. V., Gao, J.,
et al. (2010). Neural sirtuin 6 (Sirt6) ablation attenuates somatic growth
and causes obesity. Proc. Natl. Acad. Sci. U.S.A. 107, 21790–21794. doi:
10.1073/pnas.1016306107
Frontiers in Aging Neuroscience www.frontiersin.org December 2014 | Volume 6 | Article 333 | 19
Sidorova-Darmos et al. Spatial and temporal expression of sirtuins in brain
Shindler, K. S., Ventura, E., Rex, T. S., Elliott, P., and Rostami, A. (2007).
SIRT1 activation confers neuroprotection in experimental optic neuritis. Invest.
Ophthalmol. Vis. Sci. 48, 3602–3609. doi: 10.1167/iovs.07-0131
Webster, B. R., Lu, Z., Sack, M. N., and Scott, I. (2012). The role of sirtu-
ins in modulating redox stressors. Free Radic. Biol. Med. 52, 281–290. doi:
10.1016/j.freeradbiomed.2011.10.484
Wei, R., Stewart, E. A., and Amoaku, W.M. (2013). Suitability of endogenous refer-
ence genes for gene expression studies with human intraocular endothelial cells.
BMC Res. Notes 6:46. doi: 10.1186/1756-0500-6-46
Yan, W., Fang, Z., Yang, Q., Dong, H., Lu, Y., Lei, C., et al. (2013). SirT1
mediates hyperbaric oxygen preconditioning-induced ischemic tolerance in
rat brain. J. Cereb. Blood Flow Metab. 33, 396–406. doi: 10.1038/jcbfm.
2012.179
Yang, H., Yang, T., Baur, J. A., Perez, E., Matsui, T., Carmona, J. J., et al. (2007).
Nutrient-sensitive mitochondrial NAD+ levels dictate cell survival. Cell 130,
1095–1107. doi: 10.1016/j.cell.2007.07.035
Ying, W., and Xiong, Z. G. (2010). Oxidative stress and NAD+ in ischemic
brain injury: current advances and future perspectives. Curr. Med. Chem. 17,
2152–2158. doi: 10.2174/092986710791299911
Zeng, L., Yang, Y., Hu, Y., Sun, Y., Du, Z., Xie, Z., et al. (2014). Age-related decrease
in the mitochondrial sirtuin deacetylase Sirt3 expression associated with ROS
accumulation in the auditory cortex of the mimetic aging rat model. PLoS ONE
9:e88019. doi: 10.1371/journal.pone.0088019
Zerp, S. F., Vens, C., Floot, B., Verheij, M., and van Triest, B. (2014). NAD(+)
depletion by APO866 in combination with radiation in a prostate cancer model,
results from an in vitro and in vivo study. Radiother. Oncol. 110, 348–354. doi:
10.1016/j.radonc.2013.10.039
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be
construed as a potential conflict of interest.
Received: 18 August 2014; accepted: 25 November 2014; published online: 18 December
2014.
Citation: Sidorova-Darmos E, Wither RG, Shulyakova N, Fisher C, Ratnam M, Aarts
M, Lilge L, Monnier PP and Eubanks JH (2014) Differential expression of sirtuin
family members in the developing, adult, and aged rat brain. Front. Aging Neurosci.
6:333. doi: 10.3389/fnagi.2014.00333
This article was submitted to the journal Frontiers in Aging Neuroscience.
Copyright © 2014 Sidorova-Darmos, Wither, Shulyakova, Fisher, Ratnam, Aarts,
Lilge, Monnier and Eubanks. This is an open-access article distributed under the terms
of the Creative Commons Attribution License (CC BY). The use, distribution or repro-
duction in other forums is permitted, provided the original author(s) or licensor are
credited and that the original publication in this journal is cited, in accordance with
accepted academic practice. No use, distribution or reproduction is permitted which
does not comply with these terms.
Frontiers in Aging Neuroscience www.frontiersin.org December 2014 | Volume 6 | Article 333 | 20
